Ingenia Communities

INA

Ingenia Communities Group engages in managing and developing a portfolio of retirement and lifestyle communities. The company is headquartered in Sydney, New South Wales and currently employs 1,400 full-time employees. The company went IPO on 2004-07-01. The company owns, operates, and develops a portfolio of lifestyle and holiday communities across key urban and coastal markets. The company operates in five segments: Lifestyle Development; Lifestyle Rental; Ingenia Gardens; Ingenia Holidays; and Fuel, Food & Beverage Services. The Lifestyle Development segment comprises of the development and sale of lifestyle homes. The Lifestyle Rental segment comprises of long-term accommodation within lifestyle and rental communities. The Ingenia Gardens segment consists of rental villages. The Ingenia Holidays segment comprises of tourism and rental accommodation within holiday parks. The Fuel, Food & Beverage Services segment consists of the Company’s investment in service station and food & beverage operations adjoined to Ingenia Holiday communities. Its subsidiaries include Bridge Street Trust, Browns Plains Road Trust, Casuarina Road Trust, Edinburgh Drive Trust, and Garden Villages Management Trust.

BetaShares Global Income Leaders ETF

INCM

INCM.AX was created on 2018-10-18 by BetaShares. The fund's investment portfolio concentrates primarily on high dividend yield equity. The fund aims to track the performance of an index (before fees and expenses) that comprises 100 high-yielding global companies (ex-Australia) selected for their potential to generate attractive and sustainable income.

Imricor Medical Systems Inc.

IMR

Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The company is headquartered in Burnsville, Minnesota. The company went IPO on 2019-08-30. The firm is engaged in designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. Its products include Vision-mitral regurgitation (MR) Ablation Catheter, Advantage-MR electrophysiology (EP) Recorder/Stimulator and Vision-MR Dispersive Electrode. The Vision-MR Ablation Catheter is designed to work under real-time MRI guidance. Advantage-MR EP Recorder/Stimulator System provides technology that allows physicians to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment. The firm sells its products to hospitals and clinics for use in iCMR labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed.

Imugene

IMU

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.